Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report Intel FAQ API Sign In →
26 /100
MEDIUM RISK
Score updated Jul 28, 2026

OTLC — Oncotelic Therapeutics, Inc. Dilution Risk Tracker

Track OTLC dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track OTLC — Get alerts when the score changes →

As of July 28, 2026, Oncotelic Therapeutics, Inc. (OTLC) has a DilutionWatch DilutionScore of 26/100, rated MEDIUM dilution risk. Oncotelic Therapeutics, Inc. has a market capitalization of $26.67M, 444.50M shares outstanding. Key dilution vectors include 10.58M outstanding warrants, approximately 33 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
10
📊 Float Risk
2
⚠️ Warrant Exposure
15
🔄Convertible Debt

Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
27%
🔄 Reverse Split 55%
• 50-day avg $0.04 below $1 exchange minimum
🔔 Track OTLC — Get forecast alerts →

Market Data

Market Cap$26.67M
Shares Outstanding444.50M
FloatN/A
Cash$2.71M
Debt$2.72M
Short InterestN/A

Institutional Holdings

Institutional data not yet available.

Short Interest

Short Interest58.5K
Days to Cover1.0
% of FloatN/A
FINRA data as of Jul 15, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2025-12-31
xbrl XBRL WARRANT 2024-09-30
Full SEC filing analysis available with free account

Recent News

No recent news

What This Means for OTLC Shareholders

Oncotelic Therapeutics, Inc. (OTLC) has a DilutionScore of 26/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 28, 2026.

DilutionWatch tracks 10.6M outstanding warrants for OTLC. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window.

DilutionWatch tracks over 25 SEC filing types for OTLC in real-time, scanning EDGAR every 60 seconds. The DilutionWatch shows real-time score changes for OTLC alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Warrants Explained →

Understanding OTLC's Dilution Risk Factors

Primary Risk Drivers

The two most significant dilution risks for Oncotelic Therapeutics are Offering Ability and Cash Runway. Offering Ability scores at a moderate level, indicating that the company has the capacity to raise capital through equity offerings, which can lead to share issuance and dilution of existing ownership. Cash Runway is also elevated, reflecting that while the company currently holds sufficient cash for 32.8 months, it is approaching a point where further funding may be required. This increases the potential for future equity issuances that could dilute current shareholders.

Factors Currently Not a Concern

Float Risk and Warrant Exposure are currently low, suggesting minimal immediate dilution from existing float or warrant conversions. However, Float Risk could escalate if the company initiates new stock issuance programs or increases trading volume significantly. Warrant Exposure would become concerning if new warrants were issued with lower strike prices or if existing warrants were exercised en masse, increasing share count rapidly.

SEC Filings to Watch

Several filings carry significant implications for OTLC’s dilution risk. An S-3 registration statement signals a potential large-scale equity offering, directly increasing share count. A 424B5 filing often accompanies such offerings and provides details on new securities being sold. An 8-K Item 1.01 reports material events like new equity issuances or financing agreements, which could indicate upcoming dilution. A 10-Q filing may reveal changes in capital structure, including new share grants or convertible debt conversions.

How Dilution Happens

Dilution occurs when the company issues additional shares to raise capital. If Offering Ability is high, the company might file an S-3 or issue new stock under a shelf registration, increasing the total number of shares outstanding. When Cash Runway approaches critical levels, the need for funding intensifies, making such issuances more likely. Each new share issued reduces the percentage ownership of existing shareholders, directly diminishing their stake in the company.

What Would Make This Worse

If OTLC enters a phase where convertible notes are converted into equity or if it issues warrants at below-market prices, dilution could accelerate significantly. A combination of high Offering Ability and declining Cash Runway would signal an increased risk of frequent capital raises, especially if the company begins issuing shares to service debt or fund operations. Additionally, any major corporate event like a merger or acquisition that includes equity consideration would further increase share count and dilute existing holdings.

Key Insight

While current scores indicate moderate risk, the interplay between Offering Ability and Cash Runway could quickly shift if funding needs rise or cash reserves decline significantly.

How to Monitor OTLC for Dilution Risk

What This Risk Level Means

A medium dilution risk score for Oncotelic Therapeutics, Inc. (OTLC) indicates that while the company is not currently under immediate threat of excessive dilution, there are enough concerning elements in its capital structure to warrant careful attention. As a large-cap operating company with micro-cap characteristics, OTLC operates in a unique space where it has established business operations but still faces challenges typical of smaller companies. The elevated offering ability score suggests that the firm could potentially raise capital through equity offerings, which may dilute existing shareholders. For such a company, this risk level implies that although there is no immediate crisis, proactive monitoring is essential to prevent gradual erosion of shareholder value.

What Typically Happens Next

Companies with similar profiles often proceed through various capital-raising mechanisms over time. Common next steps include shelf registrations, which allow firms to issue securities at future dates without prior SEC approval, and ATM (At-the-Market) programs that enable continuous equity sales. These methods are particularly prevalent among companies in growth phases or those needing liquidity for operational expansion or debt repayment. Given OTLC’s profile, it is plausible that the company may initiate such offerings within the next 12–24 months to support its operations or strategic initiatives.

Monitoring Playbook

To effectively track dilution risk at OTLC, use DilutionWatch to set up alerts for score changes and key financial metrics. Monitor the company’s SEC filings monthly for any new equity offerings or capital structure updates. Set thresholds for DilutionScore increases above 30/100 as a warning signal, and pay close attention to changes in Offering Ability scores. When thresholds are hit, immediately review recent 8-Ks and S-1 filings for details on upcoming equity activity. Regular checks every two weeks during active periods can help catch early signs of increased risk.

Early Warning Signals

Several specific signals should raise red flags in SEC filings or score changes. First, a sudden spike in Offering Ability above 40/100 may indicate an upcoming equity offering. Second, the filing of a shelf registration statement (S-3) could signal intent to issue new shares at will. Third, an increase in outstanding warrants or convertible notes could lead to dilution if exercised or converted. These events are critical indicators that the risk profile is worsening and require immediate action.

What a Positive Resolution Looks Like

A positive shift in OTLC’s dilution risk profile would occur through a capital raise that strengthens balance sheet liquidity, such as an equity offering or debt refinancing that reduces reliance on future share issuance. Another resolution path includes the expiration or conversion of warrants without triggering new dilution. Additionally, if the company enters into a strategic partnership or acquisition that enhances cash flow and reduces the need for further equity issuance, this would significantly lower dilution risk.

Watch For

Any sudden increase in Offering Ability score or filing of shelf registration statements as early indicators of potential dilutive activity.

Full SEC filing analysis available with free account  →
Track OTLC Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking OTLC — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for OTLC
OTLC Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.